Einige Inhalte dieser Seite sind nur für Abonnenten sichtbar.       Anmelden     oder      Jetzt abonnieren!

Archiv: Unternehmen

BK - Am 25. November wird nur über das Tierseuchengesetz abgestimmt » Report
KOF Working Paper Nr. 315: R&D and Non-linear Productivity Growth of Heterogeneous Firms » Report
Roche Investor Update: Reminder: Roche conference call for investors and analysts from ESMO 2012, Tuesday, 2 October 2012, Vienna, Austria » Report
New Nestlé research collaboration seeks alternatives to salt » Report
UBS NEW ISSUE / FINAL TERMS: 8.40% p.a. AUD Kick-In GOAL on Worst of ANZ Banking Group / Commonwealth Bank » Report
BFS - Landwirtschaftliche Gesamtrechnung - Schätzung 2012 – Senkung der Produktionskosten bremst Einkommensrückgang im Agrarsektor » Report
Credit Suisse: Products in Subscription » Report
RICHEMONT ACQUIRES VARIN-ETAMPAGE AND VARINOR (‘VVSA’) » Report
Lonza and Celladon Corporation Announce Manufacturing Agreement for MYDICAR® » Report
Addex and Collaborators Awarded Swiss CTI Grant to Develop Allosteric Modulators for Neurodegenerative and Psychiatric Diseases » Report
Media Release SIX Exchange Regulation: Greater transparency - improved insight into shareholder structures » Report
Peach Property Group ist Seriensieger bei den International Property Awards Europe in London » Report
Peach Property Group AG: Umwandlung der deutschen Tochter in Aktiengesellschaft » Report
Valartis Gruppe eröffnet Bankniederlassung in Lugano und optimiert ihre Organisationsstruktur » Report
Media Release SIX Swiss Exchange and Scoach Switzerland: Key figures September 2012 » Report
SGS informs about recent California Prop 65 settlements: » Report
BIS: Implementation of capital standards: assessment reports published by Basel Committee » Report
Nestlé Investor Seminar: Video and animation available » Report
Roche Communiqué de presse: Le trastuzumab emtansine (T-DM1), produit Roche, a significativement prolongé la survie chez des personnes souffrant d’une forme agressive de cancer du sein » Report
Roche’s trastuzumab emtansine (T-DM1) significantly extended survival in people with aggressive form of breast cancer » Report